Stockscreener 앱 받기
4.40
4.14%
-0.19
시간 외 거래:
4.64
0.24
+5.45%
전일 마감가:
$4.59
열려 있는:
$4.53
하루 거래량:
794.98K
Relative Volume:
1.19
시가총액:
$224.16M
수익:
-
순이익/손실:
$-238.77M
주가수익비율:
-0.1641
EPS:
-26.808
순현금흐름:
$-216.62M
1주 성능:
+6.80%
1개월 성능:
-56.22%
6개월 성능:
-63.18%
1년 성능:
+0.00%
1일 변동 폭
$4.16
$5.48
1주일 범위
$3.79
$5.48
52주 변동 폭
$3.18
$13.50
Alumis Inc Stock (ALMS) Company Profile
명칭
Alumis Inc
전화
650-231-6625
주소
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
4.40 | 224.16M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-30 | 개시 | Oppenheimer | Outperform |
| 2024-10-31 | 개시 | Robert W. Baird | Outperform |
| 2024-10-17 | 개시 | H.C. Wainwright | Buy |
| 2024-07-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 개시 | Guggenheim | Buy |
| 2024-07-23 | 개시 | Leerink Partners | Outperform |
| 2024-07-23 | 개시 | Morgan Stanley | Overweight |
모두보기
Alumis Inc 주식(ALMS)의 최신 뉴스
Acelyrin urges stockholders to vote for proposed merger with Alumis - Yahoo Finance
ACELYRIN urges stockholders to approve Alumis merger - Investing.com
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis - The Manila Times
ACELYRIN, Inc. Urges Stockholders to Vote in Favor of Proposed Merger with Alumis Inc. Ahead of May 13, 2025 Meeting - Nasdaq
ACELYRIN Board Makes Final Push for Alumis Merger: 48% Ownership Deal at Stake in Critical May Vote - Stock Titan
Confident Outlook on Acelyrin-Alumis Merger Amid Shareholder Opposition - TipRanks
Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis - MSN
Acelyrin (SLRN) Faces Shareholder Opposition to Alumis Merger - GuruFocus
Acelyrin should liquidate instead of merging with Alumis, investor says - BioPharma Dive
Acelyrin stock gains as Trium rebuffs M&A deal (SLRN:NASDAQ) - Seeking Alpha
Alumis stock price target cut to $14 by H.C. Wainwright - Investing.com Australia
Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms - Endpoints News
Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Revised merger terms boost ACELYRIN stake in Alumis deal By Investing.com - Investing.com South Africa
Alumis, ACELYRIN amend proposed merger pact - MSN
Alumis And Acelyrin Announce Amended Merger Agreement - marketscreener.com
Alumis Raises Share Consideration for Acelyrin Acquisition - marketscreener.com
ACELYRIN, INC. Amends Merger Agreement with Alumis - TipRanks
Revised merger terms boost ACELYRIN stake in Alumis deal - Investing.com
ACELYRIN and Alumis Announce Revised Merger Agreement Enhancing Stockholder Ownership and Value - Nasdaq
Alumis and ACELYRIN Announce Amended Merger Agreement - The Manila Times
Alumis Secures Major Immunology Merger: $737M Cash Runway Stretches to 2027, 62% Shareholders Back Deal - Stock Titan
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc.SLRN - MarketScreener
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday - Benzinga
3 Biopharmaceutical Stocks Bucking the Sell-Off - MarketBeat
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alumis: Biotech's Stock Gains >100% In A MonthBut Risk Of Failure Is High (NASDAQ:ALMS) - Seeking Alpha
Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
Alumis Reaches US$465m Market Cap Benefiting Insider Stock Buying - simplywall.st
Insider Buying: Alumis Independent Director Bought US$130k Of Shares - Yahoo
Alumis and ACELYRIN announce definitive merger plan By Investing.com - Investing.com South Africa
Alumis and ACELYRIN announce definitive merger plan - Investing.com Australia
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger - The Manila Times
Major Biopharma Merger: Alumis and ACELYRIN Unite with $737M War Chest for Immune Disease Breakthroughs - Stock Titan
Simulations Plus Posts Better-Than-Expected Results, Joins Savers Value Village, MarketAxess Holdings And Other Big Stocks Moving Higher On Friday - Benzinga
Alumis Inc. CEO Martin Babler buys $100,732 in company stock By Investing.com - Investing.com Australia
Alumis Inc. director Alan Colowick buys $129,544 in stock By Investing.com - Investing.com Australia
Top Executives Make Bold Moves with Alumis Inc. Stock Purchases! - TipRanks
Alumis Inc. CEO Martin Babler buys $100,732 in company stock - Investing.com
Alumis Inc. director Alan Colowick buys $129,544 in stock - Investing.com
Alumis Inc (ALMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alumis Inc 주식 (ALMS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Colowick Alan | Director |
Apr 02 '25 |
Buy |
7.49 |
2,300 |
17,235 |
18,404 |
| Babler Martin | President, CEO and Chairman |
Apr 01 '25 |
Buy |
6.44 |
15,650 |
100,733 |
106,454 |
| Foresite Labs, LLC | 10% Owner |
Jul 01 '24 |
Buy |
16.00 |
2,500,000 |
40,000,000 |
5,584,889 |
| Foresite Capital Management V, | 10% Owner |
Jul 01 '24 |
Buy |
16.00 |
2,500,000 |
40,000,000 |
5,584,889 |
| Tananbaum James B. | Director |
Jul 01 '24 |
Buy |
16.00 |
2,500,000 |
40,000,000 |
5,584,889 |
0.39%
3.66%
자본화:
|
볼륨(24시간):